0 NASDAQ Companies - March 4, 2024LPL Financial Welcomes RFS Financial ServicesSAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that RFS Financial Securities has joined LPL […]Read More
0 NASDAQ Companies - March 4, 2024Fortinet Joins the European Commission’s Cybersecurity Skills Academy Initiative to Provide Learning Opportunities Across the European UnionSUNNYVALE, Calif., March 04, 2024 (GLOBE NEWSWIRE) — Rob Rashotte, Vice President of Global Training and Global Field Enablement at […]Read More
0 NASDAQ Companies - March 4, 2024Credo to Present at 36th Annual Roth ConferenceSAN JOSE, Calif., March 04, 2024 (GLOBE NEWSWIRE) — Credo Technology Group Holding Ltd (Credo) (NASDAQ: CRDO), an innovator in […]Read More
0 NASDAQ Companies - March 4, 2024Paylocity adds Craig Conway to Board of DirectorsSCHAUMBURG, Ill., March 04, 2024 (GLOBE NEWSWIRE) — Paylocity (Nasdaq: PCTY), a leading provider of cloud-based HCM and payroll software […]Read More
0 NASDAQ Companies - March 4, 2024Global Mofy Metaverse Wins Major New Customer OrderBEIJING, March 04, 2024 (GLOBE NEWSWIRE) — Global Mofy Metaverse Limited (the “Company” or “Global Mofy Metaverse”) (Nasdaq: GMM), a […]Read More
0 NASDAQ Companies - March 4, 2024ReShape Lifesciences® Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band® 2.0 FLEX2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for […]Read More
0 NASDAQ Companies - March 4, 2024Alto Ingredients, Inc. to Release Fourth Quarter 2023 Financial ResultsPEKIN, Ill., March 04, 2024 (GLOBE NEWSWIRE) — Alto Ingredients, Inc. (NASDAQ: ALTO), a leading producer and distributor of specialty […]Read More
0 NASDAQ Companies - March 4, 2024Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes DiseaseEncouraging preclinical studies demonstrate potential to combine AAV-ATP7A gene therapy with CUTX-101, which could be the first FDA-approved treatment for […]Read More
0 NASDAQ Companies - March 4, 2024Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024COPENHAGEN, Denmark, March 04, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate […]Read More
0 NASDAQ Companies - March 4, 2024RESEARCH FRONTIERS TO HOST YEAR-END 2023 CONFERENCE CALLWOODBURY, NY, March 04, 2024 (GLOBE NEWSWIRE) — Research Frontiers Inc. (Nasdaq: REFR) announced today that it will release its fourth quarter and […]Read More